Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 1/20 | 0.33 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.30 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.30 |
| ▸ | SLC6A13 | Q9NSD5 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL745985 | 1.00 | GABRR1 (0.33) | GABRR1SLC6A12SLC6A11SLC6A13 | |
| SCHEMBL505726 | 1.00 | GABRR1 (0.33) | GABRR1SLC6A12SLC6A11SLC6A13 | |
| SCHEMBL841973 | 1.00 | GABRR1 (0.33) | GABRR1SLC6A12SLC6A11SLC6A13 | |
| SCHEMBL18555595 | 1.00 | GABRR1 (0.33) | GABRR1SLC6A12SLC6A11SLC6A13 | |
| SCHEMBL5403763 | 1.00 | GABRR1 (0.33) | GABRR1SLC6A12SLC6A11SLC6A13 | |
| SCHEMBL18957048 | 1.00 | GABRR1 (0.33) | GABRR1SLC6A12SLC6A11SLC6A13 | |
| SCHEMBL4627762 | 0.85 | GABRR1 (0.39) | GABRR1SLC6A12SLC6A11SLC6A13 | |
| SCHEMBL3620776 | 0.85 | GABRR1 (0.39) | GABRR1SLC6A12SLC6A11SLC6A13 | |
| SCHEMBL3620778 | 0.85 | GABRR1 (0.39) | GABRR1SLC6A12SLC6A11SLC6A13 | |
| SCHEMBL19816446 | 0.85 | GABRR1 (0.39) | GABRR1SLC6A12SLC6A11SLC6A13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1978804-A2 | AMINOCYCLOHEXANES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | Merck & Co., Inc. (US) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007087231-A2 | AMINOCYCLOHEXANES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO., INC. (US) | 2007-08-02 | — | — | WO | disclosed |